KRAS and non-small cell lung carcinoma: In conclusion, although KRAS showed a prognostic effect in first-line platinum-based treatment in advanced NSCLC, this study leads us to conclude that it is not warranted to test KRAS in clinical practice, at least until a specific targeted therapy is available for this group of patients.